Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases. Open to HR+ and HR- patients. Progression of disease after CNS directed therapy or before CNS directed therapy. Evidence of crossing of blood brain barrier with this agent.
Open to HR+ and HR- patients. Progression of disease after CNS directed therapy or before CNS directed therapy. Evidence of crossing of blood brain barrier with this agent.
Inclusions/Exclusions: ECOG 0-1.
Learn More at ClinicalTrials.gov
Contact 310-582-7448 to participate.